Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases
- 3 January 2021
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 73 (2) , 215-220
Abstract
Objective: To estimate the incidence rate (IR) of psoriasis in children with inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic noninfectious osteomyelitis (CNO) with tumor necrosis factor inhibitor (TNFi) exposure as compared to children without TNFi exposure and to the general pediatric population.Methods: This was a single‐center retrospective cohort study of children with IBD, JIA, or CNO from 2008 to 2018. TNFi exposure was defined as a prescription for adalimumab, etanercept, infliximab, certolizumab, or golimumab, and the primary outcome was incident psoriasis. IRs and standardized incidence ratios (SIRs) were calculated. Cox proportional hazards models were used to assess the association of psoriasis with TNFi exposure and other risk factors.Results: Of the 4,111 children who met inclusion criteria, 1,614 (39%) had TNFi exposure and 2,497 (61%) did not, with 4,705 and 6,604 person‐years of follow‐up, respectively. There were 58 cases (IR 12.3 per 1,000 person‐years) and 25 cases (IR 3.8 per 1,000 person‐years) of psoriasis in children with and without TNFi exposure, respectively. The SIR was 18 (95% confidence interval [95% CI] 15–22) overall, 30 (95% CI 23–39) for children with TNFi exposure, and 9.3 (95% CI 6.3–14) for children without TNFi exposure. The hazard ratio of psoriasis comparing TNFi exposure to no TNFi exposure was 3.84 (95% CI 2.28–6.47; P < 0.001).Conclusion: Children with IBD, JIA, and CNO had an increased rate of psoriasis compared to the general pediatric population, with the highest rate in those with TNFi exposure.Keywords
This publication has 40 references indexed in Scilit:
- Improvement in Health‐Related Quality of Life for Children With Juvenile Idiopathic Arthritis After Start of Treatment With EtanerceptArthritis Care & Research, 2014
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatmentGut, 2013
- Infliximab‐induced Psoriasis in Children With Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2011
- A cross-sectional study using the Children’s Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scoresBritish Journal of Dermatology, 2010
- Occurrence of Pustular Psoriasis after Treatment of Crohn Disease with InfliximabPediatric Dermatology, 2010
- Nailing down the Genetic and Immunological Basis for Psoriatic DiseaseDermatology, 2010
- Psoriasis associated with ulcerative colitis and Crohn's diseaseJournal of the European Academy of Dermatology and Venereology, 2009
- Psoriasis secundaria al tratamiento con infliximab y adalimumab en la enfermedad de CrohnAnales de Pediatría, 2009
- Psoriasis after treatment of juvenile idiopathic arthritis with etanerceptAnnals of the Rheumatic Diseases, 2006
- TNFα—A PIVOTAL ROLE IN RHEUMATOID ARTHRITIS?Rheumatology, 1992